Patsy Ruegg, HT, QIHC, Director of Immunohistochemistry and Histology
Patsy Ruegg has over 30 years of experience in Histopathology, with 25 years employment at the University of Colorado Health Sciences Center Pathology Department as a Professional Research Assistant in a Hematopathology and Metabolic Bone Disease Laboratory studying bone and cartilage development and IHC techniques. She founded IHCtech LLC in 2002 to provide high quality IHC and histology services to pharmaceutical and academic clients. Patsy serves on the editorial board of the Journal of Histotechnology, Immunohistochemistry Section.
Sherri (Dovico) Saturley, HTL(ASCP), Histology Lab Manager
Sherri Saturley brings 15 years of experience in research disciplines and molecular and histology techniques. Her academic experience includes muscular dystrophy functional and structural assays, and a wide range of cell culture and molecular biology techniques. Her clinical laboratory experience includes immunofluorescence in a large dermatopathology laboratory, and immunohistochemistry and histology support for tissue-based biomarker programs.
Dr. G. David Young, DVM, DACVP, DABT
Dr. Young was previously Director of Pathology at OSI Pharmaceuticals, overseeing pathology in biomarker and preclinical development, and companion diagnostics IHC development. His experience includes oncology and biomarker research and development, digital pathology, image analysis, veterinary pathology, toxicological pathology, and toxicity testing. Management experience includes being the founding Director of the Directorate of Toxicology at the US Army Center for Health Promotion and Preventive Medicine; Director of Toxicology at Spring Valley Laboratory; Senior Vice President, Lab Services Division, TherImmune Research Corporation and Director of Pathology, OSI Pharmaceuticals, Inc. He is board certified by the American College of Veterinary Pathologists and the American Board of Toxicology.
Dr. Frank Voelker, DVM, DACVP, MS
Dr. Voelker has 35-plus years of experience in US Government, pharmaceutical industry and contract research laboratories. His experience includes areas involving experimental and discovery pathology, toxicologic pathology and toxicity testing, oncology and biomarker research, ultrastructural pathology, peer review pathology, digital pathology, image analysis and immunohistochemistry. His management background includes Chief, Division of Anatomic and Comparative Pathology, Naval Medical Research Institute, Director and founder of Electron Microscopy Laboratory, Burroughs Welcome Co., Operations Director and founder of North Carolina Pathology Laboratory, Pathology Associates Inc., Director of Pathology, TSI Mason Laboratories, Tissue Biomarker Laboratory Head, and founder, Localization Confirmation, and later Section Head, Marker Localization and Assays at Novartis Institutes for Biomedical Research. He is board certified by the American College of Veterinary Pathologists.
Dr. David Eberhard, M.D., Ph.D., Chief Medical Pathologist
Dr. Eberhard is an anatomic/molecular pathologist widely recognized for his leadership in oncology clinical trials. He was previously the Director of Clinical Trials Pathology Services at LabCorp’s Center for Molecular Biology and Pathology, where he joined after a distinguished career at Genentech and as an industry consultant. He is an Associate Professor at University of North Carolina, Chapel Hill, and has been active in developing standardized approaches for molecular pathologic analyses of solid tumors in clinical trials. Dr. Eberhard has been active in developing standardized approaches for molecular pathologic analyses of solid tumors in clinical trials, such as the publication of industry working group recommendations for EGFR testing in pathology.
Holger Lange, Ph.D., Chief Techology Officer
Dr. Lange is an image analysis expert with 20-plus years experience in all aspects of product development in a wide variety of industries (medical devices, semiconductor, defense, automotive and academia). Dr. Lange has worked for the last 8 years in the medical device industry in the US providing strong leadership and vision in the development of medical imaging systems. At STI Medical Systems, he held the positions of Director of R&D and Chief Scientist, Image Analysis. He established Computer-Aided-Diagnosis (CAD) as a new core competency and led the development of imaging systems for the in-vivodetection of uterine cervical cancer and colorectal cancer. At Aperio, Dr. Lange held the positions of Director of Product Management and Product Director, Image Analysis. In the role of the Clinical Study Director, he was responsible for Aperio’s portfolio of five 510k FDA clearances, including the industry’s first and only FDA clearances for digital read of breast cancer markers. He was also responsible for Aperio’s first product into the clinical market, a complete Digital Pathology Solution for Immunohistochemistry (IHC) incorporating automated image analysis and established Aperio as the market leader in the US Reference Lab market in the first year after product launch. Dr. Lange earned a M.Sc. in Computer Science from the Technical University (TH) of Karlsruhe, Germany, and a Ph.D. in Computer Engineering, Real Time, Robotics and Automation from the École Nationale Supérieure des Mines de Paris (EMP), France.
Joseph Krueger, Ph.D. Director of Biology
Dr. Krueger is an established cancer researcher and industry veteran, who received his Ph.D. in Cancer Biology from Wayne State University, and performed his postdoctoral research at The University of California San Diego, and The Scripps Research Institute. As a cancer researcher, Joseph was repeatedly funded and published, and continues to author collaborative publications pertaining to breast cancer progression and metastases. After his postdoctoral training, Joseph worked as a Senior Scientist at OSI Pharmaceuticals, where he joined David Young in a pivotal role to identify EMT biomarkers for their translation into clinical diagnostics. Immediately prior to joining Flagship, Joseph also served as a Principle Scientist at Pfizer in the Oligonucleotide Therapeutics Unit. Prior to his appointment as Director of Biology at Flagship, Joseph also led Flagship’s Scientific Advisory Board.
Trevor D. Johnson, M.S., Director of Tissue Analysis Services
Trevor Johnson is an expert in the use of image analysis for pharmaceutical and medial device applications. He has developed quantitative algorithms and high throughput workflow solutions for tissue analysis in several disease areas using multiple imaging modalities. Trevor has conducted training, image analysis seminars, and developed custom solutions for many large pharmaceutical and medical device companies. He has a M.S. in Engineering from UCLA and has experience working in image analysis for cancer applications with several medical device companies including Aperio and QinetiQ North America.